InvestorsHub Logo
Followers 80
Posts 11046
Boards Moderated 0
Alias Born 05/25/2017

Re: Vinpat post# 2966

Wednesday, 06/21/2017 8:57:25 PM

Wednesday, June 21, 2017 8:57:25 PM

Post# of 9941
If it's as effective as they claim it to be, then I'm thrilled. But it's yet to generate any substantial value for the company. I want to see who's knocking on their door, as they've claimed in PR. I'm still waiting to see if they can generate any partnerships with other MJ bios and pharma by leveraging their bioinformatics platform.

I was encouraged when Revive Therapeutics discussed one of their operational highlights in their Q1 2017 PR announcement:

"A Term Sheet with InMed Pharmaceuticals for the Discovery and Development of Cannabinoid-Based Therapy Targeting Kidney Diseases"


https://finance.yahoo.com/news/revive-therapeutics-ltd-announces-results-110000907.html

At the very least, I think a deal in this capacity would help confirm some value within the bioinformatics division. We're still waiting for something.

Otherwise, I think they could gain momentum if they can move their drug candidates to trials within a reasonable time frame. I think we continue to consolidate for the time being.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INM News